All Peptides
Tesamorelin/Ipamorelin

Tesamorelin/Ipamorelin

Synergistic growth hormone combo

$325/mo

Virtual consult + lab work required

This peptide requires a brief virtual visit and recent bloodwork before our team can prescribe.

Details

Virtual Consult

Our licensed provider reviews your health profile via secure video — typically 10 minutes. Required for any peptide prescription.

Required Labs

  • IGF-1
  • Comprehensive Metabolic Panel
  • Lipid Panel

Refund Policy: If found not eligible due to health reasons after consultation, you will receive a full refund.

Product Details

About Tesamorelin/Ipamorelin

Mechanism of Action

This combination leverages two complementary pathways: Tesamorelin (GHRH analog) binds to pituitary receptors to stimulate GH synthesis, while Ipamorelin (GHRP) works through the ghrelin receptor to amplify the signal. Together they create synergistic amplification—producing significantly more GH than either alone while mimicking natural pulsatile release patterns.

Scientific Background

Tesamorelin is FDA-approved for reducing visceral adipose tissue (15-20% reduction over 26 weeks). Ipamorelin is highly selective for GH release without affecting cortisol or prolactin. The combination increases peak GH levels 5-10 fold while maintaining physiological patterns and preserving normal feedback mechanisms.

Clinical Applications

Particularly effective at reducing visceral fat and improving body composition within 12-16 weeks. Used for anti-aging, athletic performance, and metabolic health. Administered 1-2 times daily, typically before bed and/or post-workout. More cost-effective than direct HGH therapy while maintaining pituitary function.

Evidence-Based

Clinical Research & Studies

Backed by peer-reviewed research from leading medical journals

2010
Peer Reviewed

Tesamorelin reduces visceral adipose tissue in HIV lipodystrophy

Multicenter trial demonstrating Tesamorelin produced significant and sustained reductions in visceral adipose tissue (-15.2%) with improvements in triglycerides and other metabolic parameters over 26 weeks.

Read Full Study
1998
Peer Reviewed

Ipamorelin: a selective growth hormone secretagogue

Research characterizing Ipamorelin as highly selective for GH release without affecting prolactin, ACTH, or cortisol, demonstrating clean pharmacology ideal for therapeutic use.

Read Full Study
1994
Peer Reviewed

Synergistic effects of GHRH and GHRP on growth hormone secretion

Study showing combined GHRH and GHRP administration produces synergistic GH release exceeding the sum of individual effects, validating the rationale for combination therapy.

Read Full Study
Explore More

Related Resources

Similar Peptide Therapies

CJC-1295
$250/mo

CJC-1295

Growth hormone support peptide

Learn More
IGF-1 LR3
$250/mo

IGF-1 LR3

Advanced muscle growth factor

Learn More
AOD-9604
$225/mo

AOD-9604

Fat burning peptide fragment

Learn More

Educational Articles

Article

Growth Hormone Peptides: CJC-1295 and Ipamorelin Explained

Read Article
Article

Visceral Fat Loss: How Peptides Target Dangerous Belly Fat

Read Article